solute carrier family 52 member 1Genealiases: GPCR42 · GPR172B · PAR2 · RBFVD · RFT1 · RFVT1
Q-omics provides the consensus-scored SLC52A1 profile across patient tissues and cancer cell-line models. SLC52A1 expression is associated with patient survival in 25 of 34 cancer types, with the highest sampling consensus in UVM. Among the 18 cancer types available for tumor–normal comparison, SLC52A1 is differentially expressed in 10, with the highest sampling consensus in HNSC. Additionally, SLC52A1 protein abundance shows 22,458 significant protein co-abundance associations, with the highest sampling consensus in GBM. Together, these results highlight UVM, HNSC, and GBM as cancer lineages where SLC52A1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for SLC52A1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes SLC52A1 survival associations across molecular data types. SLC52A1 RNA expression shows survival associations in the most cancer types (25), followed by mutation status (5) and mass-spec protein abundance (4). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible SLC52A1 RNA expression–survival associations across cancer types. High SLC52A1 expression shows unfavorable associations in UVM, KIRC and LGG, but favorable associations in CESC, KIRP and LUAD. The UVM Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify UVM as the clearest survival context for SLC52A1 RNA expression.
This table summarizes SLC52A1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 10, while mass-spec protein shows differences in 6. The strongest signals are observed in HNSC for RNA and LUAD for protein.
This table ranks reproducible tumor–normal expression differences for SLC52A1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. SLC52A1 shows lower tumor expression in COAD and KICH and higher tumor expression in HNSC, LUSC, LUAD and BRCA. The HNSC box plot shows higher SLC52A1 RNA expression in tumor versus normal tissue (log2 FC = +1.246, t-test p < 0.001).
This table shows molecular features associated with SLC52A1 in patient tissues and cancer cell lines. In patient samples, SLC52A1 shows the broadest associations at the RNA and protein expression levels, with GBM recurring as the lineage with the largest associated feature set. In cancer cell lines, SLC52A1 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in SKIN, while CRISPR and shRNA rows add functional-dependency signals in URINARY_TRACT and OESOPHAGUS.
